Methods of treating inflammatory arthritis using IL-17 antagonists
AssigneeNovartis AG
InventorsShephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Claims16
A method of treating an inflammatory arthritis associated with IL-17A, comprising administering to a patient in need thereof about 150 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
A method of treating an inflammatory arthritis IL-17A, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
Dependencies are inferred from the claim text.